Andrew Bayliffe, Chief Scientific Officer of Marengo Therapeutics and a director of the company’s board, has 25 years of leadership experience in the biopharmaceutical industry, with expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas. He held senior roles in antibody discovery and development in the US and UK and worked on early anti-CD3 antibodies, other immune engagers, and TCR-based therapeutics. Most recently, at GlaxoSmithKline (GSK), he served as head of the Fibrosis and Lung Injury Discovery Unit at GSK’s R&D headquarters in Stevenage, UK.

Andrew is a venture partner at ATP (Apple Tree Partners) and an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast. He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.